Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation

Transplantation. 2017 Sep;101(9):2092-2101. doi: 10.1097/TP.0000000000001545.

Abstract

Background: Natural killer (NK) cell alloreactivity is favored after double umbilical cord blood transplantation (dUCBT) in which cord blood (UCB) units and patients are often HLA class I mismatched. Generally, only 1 UCB unit persists after dUCBT. We hypothesize, that NK cell alloreactivity mediated by killer cell immunoglobulin-like receptor (KIR)-HLA interactions may explain the dominance of 1UCB unit over the other after dUCBT.

Methods: We investigated the impact of KIR NK cell alloreactivities on the dominance of 1 full UCB unit in 50 dUCBT. We analyzed the effects of the KIR/HLA genetic incompatibilities and studied cord blood cells at both the phenotypic and functional levels.

Results: The genetic combination of KIR3DL1 loser UCB unit/Bw4 winner UCB unit determined both the dominance of 1 UCB unit (hazards ratio, 2.88 [1.32-6.27], P = 0.0077) and correlated with an increased incidence of relapse (hazards ratio, 4.91 [1.39-17.3], P = 0.0134). It is interesting to note that cord blood cells exhibited extremely low HLA class I expression. Moreover, resting cord blood KIR3DL1 NK cells exhibited a basal alloreactivity against Bw4 target cells that increased upon activation, thus triggering death by apoptosis.

Conclusions: Our unicentric study suggests, for the first time, the significant impact of KIR NK cell alloreactivity in the determination of which UCB unit will dominate in dUCBT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cells, Cultured
  • Cord Blood Stem Cell Transplantation / adverse effects*
  • Cytotoxicity, Immunologic
  • France
  • Genotype
  • Graft vs Host Disease / immunology*
  • Graft vs Host Disease / pathology
  • HLA Antigens / genetics
  • HLA Antigens / immunology*
  • Histocompatibility*
  • Humans
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / pathology
  • Lymphocyte Activation*
  • Phenotype
  • Receptors, KIR3DL1 / genetics
  • Receptors, KIR3DL1 / immunology*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • HLA Antigens
  • KIR3DL1 protein, human
  • Receptors, KIR3DL1